Olatunji Alese, MD
Hematology & Oncology · Atlanta, GANPI 1053631010
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $92,856 of the $136,996 with a category attached, or 67.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 17.9%. Reporting peaked in 2024 at $52,831 and has fallen 70.7% since, to $15,473 in 2025. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $867.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$24K
- Taiho Oncology, Inc.$24K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Exelixis Inc.$15K
- Ipsen Biopharmaceuticals, Inc$9K
- Incyte Corporation$7K
- plus $34K from 13 others
Across 259 payments — averaging $59,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$7.9M
- Ipsen Biopharmaceuticals, Inc$3.8M
- Boehringer Ingelheim$1.6M
- E.r. Squibb & Sons, L.L.C.$831K
- Pfizer$413K
- AstraZeneca$251K
- plus $657K from 11 others
What the payments were for
- Consulting fees$92,85668%
- Speaking & faculty fees$23,91417%
- Travel & lodging$16,36212%
- Food & beverage$3,8023%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 28 | $24,466 |
| Taiho Oncology, Inc. | 7 | $23,663 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $23,306 |
| Exelixis Inc. | 42 | $15,470 |
| Ipsen Biopharmaceuticals, Inc | 9 | $9,298 |
| Incyte Corporation | 9 | $7,281 |
| AbbVie | 3 | $5,538 |
| Array Biopharma Inc | 2 | $5,520 |
| Eli Lilly | 13 | $5,077 |
| Aadi Bioscience, Inc. | 7 | $3,415 |
| GSK | 2 | $3,200 |
| Boehringer Ingelheim International GmbH | 10 | $2,980 |
| AstraZeneca | 3 | $2,507 |
| Boehringer Ingelheim | 1 | $2,220 |
| Seagen Inc. | 1 | $1,375 |
| R-pharm US LLC | 2 | $1,323 |
| Tesaro, Inc. | 4 | $161 |
| Pfizer | 1 | $130 |
| Bayer | 2 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,996 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 17 | $117,141 |
| Lanreotide Acetate | 12 | $98,911 |
| CreonLipase/Protease/Amylase | 22 | $69,048 |
| Imatinib Mesylate | 20 | $9,371 |
| Ondansetron Hcl | 24 | $821 |
| Prochlorperazine Maleate | 27 | $251 |
| Dexamethasone | 15 | $244 |
| Oxycodone Hcl | 21 | $141 |
| Pantoprazole Sodium | 18 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Taiho Oncology, Inc.Lonsurf | $23,663 | $117,14117 claims |
| AbbVieCreon | $5,538 | $69,04822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Atlanta
- Ticiana LealAtlanta$450K
- Ajay NookaAtlanta$222K
- Rodolfo BordoniAtlanta$159K
- Mehmet BilenAtlanta$150K
- Gina D AmatoAtlanta$97K
- Otis BrawleyAtlanta$89K
- Conor SteuerAtlanta$86K
- Fuad El RassiAtlanta$84K
- Jonathon CohenAtlanta$84K
- Ioana BontaAtlanta$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.